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Abstract
Background: Recent evidences show that Pulmonary Rehabilitation (PR) is effective in patients with Interstitial Lung
Disease (ILD). It is still unclear whether disease severity and/or etiology might impact on the reported benefits. We
designed this prospective study 1) to confirm the efficacy of rehabilitation in a population of patients with ILDs and
2) to investigate whether baseline exercise capacity, disease severity or ILD etiology might affect outcomes.
Methods: Forty-one patients (IPF 63%, age 66.9 ± 11 ys) were enrolled in a standard PR course in two centers.
Lung function, incremental and endurance cyclo-ergometry, Six Minutes Walking Distance (6MWD), chronic dyspnea
(Medical Research Council scale-MRC) and quality of life (St. George Respiratory Questionnaire-SGRQ) were recorded
before and at the end of PR to measure any pre-to-post change. Correlation coefficients between the baseline
level of Diffuse Lung Capacity for Carbon monoxide (DLCO), Forced Vital Capacity (FVC), 6MWD, power developed
during incremental endurance test, GAP index (in IPF patients only) and etiology (IPF or non-IPF) with the functional
improvement at the 6MWDT (meters), at the incremental and endurance cyclo-ergometry (endurance time) and the
HRQoL were assessed.
Results: Out of the 41 patients, 97% (n = 40) completed the PR course. Exercise performance (both at peak load and
submaximal effort), symptoms (iso-time dyspnea and leg fatigue), SGRQ and MRC significantly improved after PR
(p < .001). Patients with lower baseline 6MWD showed greater improvement in 6MWD (Spearman r score = − .359,
p = .034) and symptoms relief at SGRQ (r = −.315, p = .025) regardless of underlying disease.
Conclusion: Present study confirms that comprehensive rehabilitation is feasible and effective in patients with ILD of
different severity and etiology. The baseline submaximal exercise capacity inversely correlates with both functional and
symptom gains in this heterogeneous population.
Keywords: Pulmonary rehabilitation, Interstitial lung diseases, Endurance test, Endurance time, Functional performance
* Correspondence: roberto.tonelli@me.com
1Respiratory Diseases Unit-AOU Policlinico, Department of Medical and
Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tonelli et al. BMC Pulmonary Medicine  (2017) 17:130 
DOI 10.1186/s12890-017-0476-5
Background
Interstitial lung diseases (ILDs) comprise a heterogeneous
group of chronic conditions characterized by lung paren-
chymal involvement with different degrees of inflamma-
tion and fibrosis resulting in impaired gas exchange and
restrictive physiology. Clinically, the development of irre-
versible and progressive parenchymal fibrosis leads to
ventilatory constraint and abnormal lung mechanics with
limited exercise capacity and dyspnea on exertion [1]. In
particular, the impaired level of gas exchange seems to be
the major cause leading to exercise intolerance in these
patients [2]. Consequently, as ILD progresses, the patient’s
daily activities decline early following symptoms (short-
ness of breath, tiredness, muscle fatigue). This reduction
in everyday performance begins even before that ventila-
tory limitation with functional impairment occurs [3]. Fur-
thermore ILD patients experience greater physical and
social limitations once ventilatory constraint has estab-
lished, reducing their functional reserves [2]. Finally, due
to the progressive exercise limitation, individual’s health-
related quality of life (HRQoL) is markedly affected [4].
Thus, the proper management of dyspnea represents a
critical need for patients suffering from ILD. Pulmonary
rehabilitation (PR) programs have been widely assessed
and validated in patients with Chronic Obstructive
Pulmonary Disease (COPD) [5], for which they have
been proved to be effective in reducing respiratory and
non-respiratory (i.e. peripheral muscle fatigue) symptoms
and improving functional performance status which is
consistent with improvement in HRQoL [6]. Nonetheless,
there is a growing body of evidence showing that PR con-
sisting of tailored and supervised training on aerobic and
resistance exercises, breathing techniques and education
sessions focused on self-management of symptoms and
physical activity promotion could improve outcomes like
dyspnea, functional capacity and quality of life also in pa-
tients with ILD [7–11]. However, the ultimate guidelines
on diagnosis and management of Idiopathic Pulmonary
Fibrosis (IPF) [1] provide a weak recommendation for PR
in this particular form of ILD, due to the low quality of
evidence on the real achievable gain. Furthermore, there is
still no clear evidence regarding which type of ILD form
(idiopathic VS non idiopathic) could benefit the most
from a PR program.
With reference to this, Huppmann and colleagues
prospectively investigated the effect of a 4-week PR pro-
gram in a wide population of 402 patients with ILDs. The
authors reported clinically relevant improvements in both
functional exercise capacity and in HRQoL independent
on the underlying disease (which were IPF, cryptogenic
organizing pneumonia, hypersensitivity pneumonitis,
sarcoidosis, or others) [12]. However, in a systematic re-
view by Holland et al., patients with IPF seem to have
lower improvement in functional capacity following PR as
compared with others suffering from different etiologies
of ILD [13].
Even more, the impact of disease severity on PR out-
comes seems not to be well clarified in patients with ILDs.
Lower lung derangement, less oxyhaemoglobin desatur-
ation and lower level of secondary pulmonary hypertension
have been associated with greater improvement in func-
tional capacity in patients with IPF but were not predictors
of benefit in those with other ILDs [14]. This might indicate
that PR is likely to be effective in IPF at early stage of the
disease, whereas different etiology of ILD may benefit
regardless of disease severity. Indeed, in a prospective
multicenter cohort study, Ryerson and colleagues had
showed that patients with ILD (of whom around only
one third were IPF) and a low functional capacity at
baseline had greater benefit from rehabilitation [3].
In summary despite the beneficial effect of PR in ILD
patients has been supported by a growing body of evi-
dence, the ultimate IPF guidelines still provide a weak
recommendation for PR [1] and 2) the impact of disease
severity and ILD etiology on PR outcomes remains not
well understood. The present prospective observational
two-center study has been designed 1) to confirm the
positive impact of pulmonary rehabilitation delivered
both as in- and outpatient program in a population of
patients with ILDs of different etiology [15] and 2) to
further investigate whether baseline exercise capacity,
disease severity or ILD etiology might differently affect
clinical outcomes following a standard PR course.
Methods
Patient population and study design
Between January 2013 and January 2015, 41 consecutive
patients with ILDs of different etiology were prospectively
enrolled as in-patients (n = 30, 73%) or out-patients
(n = 11, 27%) to perform a standard comprehensive PR
program [6] both at “Villa Pineta” Rehabilitation Hospital
in Pavullo n/F (Modena) and at “Don Gnocchi” Institute
in Firenze. Patients not fulfilling criteria for PR [6] were
excluded. Diagnosis of ILD was performed according to
the ATS/ERS international consensus classification of
idiopathic interstitial pneumonias [16].
The study had a prospective design. It was approved
by the local review board and the Ethics Committee at
both Institutions. All the individuals gave their informed
consent to participate and to publish data on scientific
journals.
The study flowchart is shown in Fig. 1.
Assessment and outcomes
Functional status
Routine pulmonary function tests (forced vital capacity-
FVC and forced expiratory volume in 1st second-FEV1)
and diffusive lung capacity (DLCO), obtained with subjects
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in a comfortable seated position, were measured according
to the American Thoracic Society/European Respiratory
Society (ATS/ERS) recommendations [17]. Lung volumes
were measured by volume-displacement body plethysmo-
graph (Autobox DL 6200; SensorMedics, Yorba Linda,
CA); the normal reference values were those by the
European Community for Coal and Steel [18].
Blood gases were measured by an automated analyzer
(IL-1650, Instrumentation Laboratory, Milan, Italy for the
center of Modena and ABL 800, Radiometer, Copenaghen
for the center of Florence) from an individual’s arterial
sample taken when in resting condition while breathing
room air.
Disease severity score of IPF patients was recorded
using the GAP-staging system [19], which includes
gender, age, forced vital capacity (FVC) and diffusion
lung capacity for carbon monoxide (DLCO).
Incremental exercise testing (1-min increments of
10 W) to a symptom-limited maximum was performed
on an electronically braked ergometer (Ergo-Metrics
800 s; SensorMedics) for lower limbs pre-post PR. The
patients were familiarized with the apparatus days prior
to the test; they were encouraged to keep exercising for
as long as possible while pedaling at 50 to 60 rpm and
were instructed to maintain work levels until they
reached a symptom-limit. In addition, the six-minute
walked distance (6MWD) was carried out according to
the ATS/ERS guidelines [20]. All the subjects underwent
two consecutive tests with the best result taken as
representative.
A pulmonologist or a cardiologist and a rehabilitation
therapist, unaware of the study purposes, closely super-
vised each exercise session; during the session, heart rate
and peripheral oxygen saturation (SpO2) were monitored
continuously.
Symptoms and health-related quality of life
The perceptions of dyspnea and limb efforts were
determined at the beginning and at the end of 6MWD
and every 2 min during cycle-ergometry using the
modified Borg scale [21]. This scale is a vertical list
with labeled categories describing increasing intensities of
the perceived symptom (dyspnea or fatigue). Subjects
were asked to rank the overall intensity of respiratory
discomfort and leg effort by pointing to a score on a
large scale from zero (none, i.e. no sensation at all) to
10 (maximum, i.e. the most severe sensation they had
ever experienced).
Chronic exertional dyspnea was assessed by using the
5-point (0 to 4) MRC scale [22].
The St. George Respiratory Questionnaire (SGRQ) as
validated into the Italian version was used to assess the
patient’s health-related quality of life (HRQoL) [23].
Total and component (symptoms, activity and impacts)
scores were recorded for analysis. This questionnaire
was previously used also in patients with ILD [24, 25].
Fig. 1 Study flowchart
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Maximal load and level of symptom achieved during
incremental exercise test, endurance time and dyspnea
recorded at iso-time during endurance test, distance
walked, chronic dyspnea and HRQoL were used as out-
come measures, suitable for a pre-to-post comparison.
Pulmonary rehabilitation program
The two centers involved provided a standardized similar
and shared PR course as recommended [6, 26]. PR pro-
gram consisted of: 6-h/week individually exercise training,
including endurance training for upper and lower limbs, 2
session of breathing techniques lasting 30 min for four to
five times per week and 3 sessions of group education per
week. Exercise training consist of aerobic (treadmill,
stationary bikes) and resistance training (light weights,
resistance bands) and included supervised cycle and sup-
ported arm ergometry, and leisure walking used as out-
come measures, suitable for a pre-to-post comparison.
Breathing training consisted of breathing techniques
(controlled and diaphragmatic breathing), pacing and
energy conservation. Supplemental oxygen was delivered
to maintain normal level of oxygen saturation. PR was
tailored on the patient’s functional status and perform-
ance. The educational topics included medication and
oxygen use, nutrition, panic control and relaxation tech-
niques, as well as psychosocial support and issues of palli-
ation and/or end-of-life related to the disease progression
[6]. If needed, patients received psychosocial support. The
PR program lasted at least 24 sessions of rehabilitation
training and was conducted 6 days a week, once daily the
first week and twice daily thereafter. Each rehabilitation
session lasted at least 3 h.
Statistical analyses
Per-protocol analysis was conducted by means of
STATA 11.2 statistical package (StataCorp, Texas, USA).
Data were obtained from prospectively maintained medical
records and computerized databases. A p value lower than
0.05 was required for significance.
We used Kolmogorov–Smirnov test in order to assess
the distribution of data showing that all data follow a
normal distribution. Pre to post comparisons were per-
formed by paired and unpaired t-test, χ square test and
Wilcoxon rank sum test. Changes from baseline in
6MWDT (meters) and in Endurance Time (minutes)
and SGRQ (total score) following PR were considered as
indicators of improvement in functional capacity and
HRQoL respectively [3, 27]. The statistical power ex-
pected for the present study population was calculated
with reference to the primary outcomes and the mini-
mum difference appreciable by our sample was assessed
at ≥3% of baseline values for major outcomes.
With reference to etiology patient were divided in
“IPF” and “non IPF”. Baseline DLCO, FVC and GAP
index (for IPF patients only) were considered indicators
of lung derangement and disease severity. The distance
covered at 6MWD and the power (watt) developed
during the incremental endurance test at baseline were
taken to assess functional performance.
To asses correlation between baseline exercise capacity,
disease severity and ILD etiology with functional and
symptoms improvement a bivariate analysis by Spearman
rank correlation coefficient was applied.
Results will be described as mean ± standard deviation
(SD), except otherwise indicated.
Results
Forty out of 41 patients referred to PR completed the pro-
gram; one subject with hypersensitivity pneumonitis (non
IPF) dropped out as he developed bacterial pneumonia in
hospital, once he had completed 20 rehabilitation sessions.
Among patients who completed the program the number
of rehabilitation sessions performed ranged from 26 to 32
and did not differ between in and outpatients (p = .15).
Demographics and baseline data on function, symp-
toms, disease etiology and severity are shown in Table 1.
Baseline features were comparable with no statistically
significant difference between patients enrolled in the
two centers and involved in the in- and outpatient pro-
gram. Mean DLCO and volumes (overall mean FVC
74.5 ± 21.42% of predicted value) indicated a mild-to-
moderate lung restriction. Notably, the overall mean
GAP index score in IPF patients was 3.74 ± 1.69 over a
maximum of 7. Twelve subjects presented abnormal gas
exchange on effort and were prescribed for using oxygen
as a supportive therapy. At baseline, the overall mean
distance covered at the 6MWDT was 376.8 m ± 94.6 m
and the overall mean endurance power developed during
incremental exercise test was 57.5 w ± 23.7 w, which
revealed a substantial reduction of exercise capacity both
at submaximal and maximal performance test. Among
patients with ILD other than IPF, 8 had pulmonary fibro-
sis associated to collagen vascular disease, 4 had chronic
hypersensitivity pneumonitis, 2 had sarcoidosis and 1
had asbestos-related ILD.
In Table 2 outcome measures and their absolute or
relative change following PR are displayed: the standard
rehabilitation course resulted in a significant improvement
in all the pre specified outcomes, being not influenced by
PR setting and center of enrollment (see Fig. 2). Distance
covered, peak and endurance exercise performance in-
creased after PR, while symptoms score at peak exercise
or iso-time decreased substantially. Notably, SGRQ score
improved in all the categories. The minimal clinically im-
portant difference (MCID) in 6MWD and SGRQ was
achieved by 75.6% and 80.3% of patients respectively. Nor
IPF diagnosis neither other baseline features significantly
influenced the achievement of the MCID in the major
Tonelli et al. BMC Pulmonary Medicine  (2017) 17:130 Page 4 of 9
outcomes. Lower 6MWD covered at baseline significantly
correlated with improvement in 6MWD (Fig. 3, panel f),
endurance time at cycle ergometer (Fig. 5, panel f) and in
SGRQ (total score) (Fig. 4, panel f) following PR, whereas
power reached at incremental endurance test, FVC,
DLCO, GAP index score and etiology did not (see also in
Figs. 3, 4 and 5 panels a to e).
Discussion
In this study we evaluated the impact of a standard
comprehensive PR program conducted in the real life
in patients with ILD of different etiology, functional
performance and lung impairment. Overall, findings
confirm that these patients are likely to gain large bene-
fits from PR delivered as in and outpatient setting, both
in terms of exercise performance, symptoms, and per-
ceived quality of life regardless of underlying disease. In
particular, our study extends the concept that patients
with both IPF and non-IPF showing lower submaximal
exercise capacity at baseline are more likely to benefit
in terms of exercise performance and HRQoL.
Multiple aspects deserve discussion.
First, the extent of improvements experienced by the
enrolled ILD-patients seems even greater than that re-
ported in previous studies. In particular, the absolute
change in the average distance covered at the 6MWDT
Table 1 Baseline features of study population
Baseline characteristics Overall Center of provenience p Setting of PR program p
Aa (n. 20) Bb (n. 21) In (n. 30) Out (n. 11)
Age (years) 66.9 ± 10.9 67.8 ± 9.7 65.4 ± 11.1 .74 70.3 ± 15.7 62.4 ± 7.1 0.12
Gender (males: females) 27: 14 13: 7 14: 7 .99 21: 9 8: 3 0.99
BMI (kg/m2) 28.1 ± 3.4 27.8 ± 2.4 28.3 ± 1.1 .84 27.6 ± 7.4 29.3 ± 1 0.46
Diagnosis (IPF: non IPF) 26: 15 13: 7 13: 8 .99 18: 12 8: 3 0.72
Smoking history (yes: no) 30: 11 16: 4 14: 7 .48 21: 9 9: 2 0.69
GAP index -for IPF only- 3.74 ± 1.69 4.14 ± 2.19 3.24 ± 1.15 .11 4.36 ± 3.19 3.24 ± 1 0.345
Inpatients (in: out) 30: 11 15: 5 15: 6 .99 – – –
O2 therapy (yes: no) 12: 29 5: 15 7: 14 .73 10: 20 2: 9 .46
O2 therapy (continuous: during effort) 8: 4 3: 1 5: 3 .99 7: 3 1: 1 .99
Arterial pO2 (mmHg) 68 ± 12 70 ± 10 66 ± 7 .14 64 ± 14 71 ± 3 .11
Arterial pCO2 (mmHg) 37 ± 4 38 ± 5 37 ± 2 .4 37 ± 4 37 ± 1 .99
FVC (% predicted) 74.5 ± 21.4 72.4 ± 16.4 75.8 ± 7.4 .39 70.4 ± 16.4 77.8 ± 8.4 .16
FEV1 (% predicted) 78.7 ± 20.7 79.6 ± 19.6 77.4 ± 21.7 .74 72.6 ± 19.6 79.4 ± 12.7 .29
DLCO (% predicted) 45.5 ± 20.9 43.3 ± 21.2 46.9 ± 19.5 .57 42.4 ± 19.2 47.9 ± 12.5 .38
aCenter A = “Don Gnocchi” Institute, Firenze, Italy
bCenter B = “Villa Pineta” Rehabilitation Hospital in Pavullo n/F, Modena, Italy. Continuous variables are indicated as mean ± standard deviation, non continuous as n
Table 2 Outcome measures with absolute and relative change following PR
Outcomes n Before PR Post PR Absolute change Relative change (%) p
MRC 40 2.8 ± 0.8 1.7 ± 1.1 - 1.1 ± 0.8 −40.8 ± 35 <.001
SGRQ (Total) 39 50.6 ± 13.9 38.5 ± 13.7 - 12.1 ± 11.1 −23.3 ± 19 <.001
SGRQ (Activity) 39 67.6 ± 14 589 ± 19.6 - 8.8 ± 17.6 −12.5 ± 24.7 0.009
SGRQ (Impact) 39 43.7 ± 19.1 29.9 ± 15.9 - 13.7 ± 14.6 −29.9 ± 41.5 <.001
SGRQ (Symptoms) 39 40.4 ± 20.9 26.7 ± 20.8 - 17 ± 19.8 −36 ± 22.1 <.001
6MWDT (m) 39 376.8 ± 94.6 430.9 ± 96.4 54.1 ± 55.4 16.7 ± 37.8 <.001
Dyspnea 6MWTD (Borg Scale) 39 5.2 ± 2.3 3.8 ± 2.2 −1.4 ± 2.1 −23.4 ± 40.1 .015
Leg fatigue 6MWTD (Borg Scale) 39 3.5 ± 2.7 2 ± 2.2 −1.6 ± 1.5 −48.1 ± 71.5 .006
Cycle dyspneaa (Borg scale) 40 6.1 ± 2 4.2 ± 2.7 - 1.8 ± 1.9 −33 ± 35.1 <.001
Cycle leg fatiguea (Borg scale) 40 5.9 ± 2.1 3.7 ± 2.7 - 2.2 ± 2 −39.5 ± 106 <.001
Cycle endurance time (min) 40 7.7 ± 3.8 12.5 ± 8.4 4.8 ± 6.9 66 ± 108.1 <.001
Cycle endurance power (watt) 40 57.5 ± 23.7 88.2 ± 57.1 31 ± 53.5 63.4 ± 33.9 .003
Each outcome value is reported as mean value ± standard deviation (SD); p value are referred to relative changes
aCycle dyspnea and leg fatigue were assessed at isotime
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after PR has been 54.1 ± 55.4 m (+ 16.7% from baseline,
p < .001), compared to the 44.34 m (95% CI 26.04 to
66.64) as reported in a recent meta-analysis [28, 29]; fur-
thermore the average reduction seen in the MRC score
for dyspnea has been greater than 1 (− 1.1 ± 0.8,
p < .001). The observed major benefits might be due to
the peculiar baseline features of the study population,
constituted of ILD patients with mild to moderate
impairment of respiratory function and a measurable
exercise capacity (although substantially reduced as ex-
pected) even at peak intensity. The permissive level of
lung function derangement let almost all the patients to
complete the rehabilitation program (only 1 patient left
the study protocol for the onset of infectious pneumonia),
with increased exercise tolerance both at submaximal and
maximal performance. Thus we can postulate that less
deranged lung in interstitial diseases may provide greater
chance to successfully undertake and complete rehabilita-
tion training, issuing its positive results over a limited
baseline functional capacity.
Second, data from our study also show how ILD patients
of different nature and severity could equally gain benefits
from PR without any significant difference in terms of
improvement. In particular the nature of the fibrotic lung
Fig. 2 Effect of PR setting and center of enrollment on PR effectiveness expressed in terms of relative change from baseline. Cycle dyspnea and
leg fatigue were assessed at isotime. * Center A = “Don Gnocchi” Institute, Firenze, Italy. ** Center B = “Villa Pineta” Rehabilitation Hospital in
Pavullo n/F, Modena, Italy
Fig. 3 Correlation between baseline FVC (panel a), DLCO (panel b), GAP index (panel c), ILD etiology (panel d), power developed at endurance
test (ET) (panel e), distance covered at 6MWDT panel f) and change in 6MWDT distance (%) after PR. Statistical significant is indicated by p value
while correlation is indicated by the Pearson’s correlation coefficient r
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changes does not impact the positive effect of PR. As a
matter of fact, regardless of the etiology, patients affected
with ILD share common clinical features with distressing
dyspnea, exercise intolerance and persistent cough [3].
What might differentiate IPF from other forms of ILD, es-
pecially non-idiopathic, is the systemic involvement of the
underlying disease that could affect the adherence to
exercise training, thus reducing the effectiveness [10].
Therefore, our study has demonstrated that PR could pro-
vide benefits irrespectively of the nature of ILD and the en-
suing eventual systemic involvement. Researches have
widely questioned the impact of disease severity and the
subsequent functional limitation on the effect of PR in ILD
patients [8]. Ryerson and colleagues showed how a lower
Fig. 4 Correlation between baseline FVC (panel a), DLCO (panel b), GAP index (panel c), ILD etiology (panel d), power developed at endurance
test (ET) (panel e), distance covered at 6MWDT panel f) and change in SGRQ (total) after PR. Statistical significant is indicated by p value
while correlation is indicated by the Pearson’s correlation coefficient r
Fig. 5 Correlation between baseline FVC (panel a), DLCO (panel b), GAP index (panel c), ILD etiology (panel d), power developed at endurance
test (ET) (panel e), distance covered at 6MWDT panel f) and change in Endurance Time after PR. Statistical significant is indicated by p value while
correlation is indicated by the Pearson’s correlation coefficient r
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baseline 6MWD could predict larger improvement in dis-
tance covered after PR [3]. Similarly, those with relatively
higher levels of baseline dyspnea experienced major
prolonged symptoms relief [14]. Conversely, other studies
show that greater and sustained improvements in func-
tional capacity following exercise training have been de-
scribed when patients present a higher baseline FVC and
less desaturation on the baseline 6MWDT [30], suggesting
that PR could be more effective if offered earlier in the
disease course. This discordance may be explained by
differences in the patient population (e.g. the presence of
comorbidities) or study design (cohort vs randomized
trial). In our study the different level of lung derangement
expressed by levels of FVC and DLCO do not affect PR
benefits. This suggests that motivated ILD patients with
functional impairment from mild to moderate should be
early referred to PR because they are likely to benefit.
Third, our study confirms that patients with lower base-
line functional performance may experience the greater
clinical benefit in terms of exercise capacity and symp-
toms relief. These data confirmed what already reported
by Ryerson and colleagues [3], adding a significant correl-
ation with lower submaximal baseline functional capacity
and greater HRQoL improvement after PR. It seems inter-
esting to stress that the power reached at incremental
endurance test performed at baseline did not inversely
correlate with functional improvement after PR. In a rela-
tively recent study, Holland and colleagues directly com-
pared the cardiorespiratory responses during 6MWDT
and cardiopulmonary exercise test (CPET) in patients with
ILD [31]. They showed how desaturation on exertion was
higher during 6MWDT than during CPET independently
on the physiological load. This seems due to the increased
alveolar ventilation reached during cycling, with a subse-
quent offset of oxyhaemoglobin desaturation through aug-
mentation in partial pressure of oxygen in arterial blood
(PaO2). They conclude that 6MWDT, eliciting high but
submaximal functional responses in ILD patients, is a
unique tool to derive information across the range of dis-
ease severity. Our study enhances this concept suggesting
that 6MWDT seems even more sensitive than incremental
endurance test in identifying ILD patients with greater
functional improving potential. It is worth to note that
patients with a higher baseline 6MWD showed less in-
crease in distance covered after PR, probably due to a
reduced capacity for further improvement. Moreover a
greater 6MWDT was not correlated with lack of improve-
ment in other functional or symptomatic outcomes, thus
confirming that physical intervention (rehabilitation) is a
critical approach even in patients with a higher level of
baseline exercise capacity.
Our study presents several limitations; first of all this
was a preliminary trial whose explorative nature resulted
in the lack of a sample size computation analysis. A
subsequent study with a sample size computed on the
basis of the evidence provided by the present study is
needed. Secondly the limited size of the study popula-
tion did not allow detailed subgroup analyses. In
addition, the lack of a control group could limit the
likely significance of our findings, while the lack of
follow-up after PR did not allow to assess the persistence
of the reported benefits over time nor comparing it be-
tween diagnosis (e.g. IPF vs non-IPF). Furthermore, all
the patients enrolled showed a baseline mild to moderate
impairment of lung function, without any case of severe
lung derangement. This did not let to evaluate the effect
of PR model on the more compromised patients and to
investigate whether a more severe functional limitation
could significantly affect the improvement after PR.
Future research is therefore required to better define
the subset of ILD patients that can benefit most from
exercise training and investigate whether different
and/or more specific modalities should be used to en-
hance gains following PR in patients with more severe
disease.
Conclusions
There is a growing body of evidence to support pulmonary
rehabilitation as a fundamental treatment for patients with
lung fibrosis that should be early referred to tailored
exercise programs. Our study has demonstrated that in
ILD patients the level of lung derangement or etiology
at baseline do not affect outcomes improvement follow-
ing rehabilitation. Moreover, a lower derangement in
lung function may provide a greater chance to success-
fully undertake and complete PR. Since the degree of
improvement across measured outcomes is remarkable,
this suggests that pulmonary rehabilitation should be a
first line therapy for managing symptomatic patients
with ILD of different nature and mild to moderate
severity.
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